8-K ·Filed Jun 9, 2026

PTCT

PTC THERAPEUTICS, INC.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001104659-26-071916
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

No material trading signal. The board departure is routine and the consulting arrangement ensures knowledge continuity. Monitor for any future board departures that might signal governance concerns, but this filing alone does not warrant action.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
PTCT ▼ -2.66% at T+60d
NEUTRAL call ✗ call lost -2.66% · α vs SPY -9.24% · entry $73.35 → $71.40
Entry anchored
Jun 9, 03:59 PM ET
via exchange tick
T+1d
+1.85%
call +1.85% · α +0.15%
$74.71
settled 4mo ago
T+5d
-0.11%
call -0.11% · α -3.54%
$73.27
settled 4mo ago
T+20d
+22.09%
call +22.09% · α +18.46%
$89.55
settled 3mo ago
T+60d
-2.66%
call -2.66% · α -9.24%
$71.40
settled 29d ago

Price Chart

Loading chart...

Executive Summary

Board member Alethia Young resigned effective June 8, 2026, citing a need to focus on other work commitments, with no disagreement with the company. She immediately entered into a one-year consulting agreement at $4,166.67/month, retaining her unvested equity awards which will continue to vest during the consulting term. This is a routine board transition with continuity preserved through the consulting arrangement.

Key Facts

  • Alethia Young resigned from the board effective June 8, 2026
  • Resignation was not due to any disagreement with the company
  • Entered into a consulting agreement through June 8, 2027 at $4,166.67/month
  • Unvested stock options and RSUs will continue to vest during the consulting term
  • Consulting agreement is terminable by either party on 30 days' notice

Financial Impact

Monthly consulting fee of $4,166.67 for one year totals approximately $50,000 — immaterial for a $5.9B market cap company

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (21 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-071916
Document: tmb-20260608x8k.htm0001104659-26-071916
Document: 0001104659-26-071916-index-headers.html0001104659-26-071916
Document: 0001104659-26-071916-index.html0001104659-26-071916
Document: 0001104659-26-071916.txt0001104659-26-071916
15 reports for PTCT
Performance horizon
100% Hit rate 4 of 4 directional calls best @ T+60▲ +19.01%Apr 28, 2026
Filters
Rows
Reports for PTCT — sortable, filterable
TypeNow
Aug 21, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$69.82 $65.26▼ −6.53%▼ −6.00%$63.46 (−9.11%)
Jul 16, 2026
11w ago
Press Release
BEARISH ★ 7/10
$78.52 $71.97▲ +8.34%▲ +11.96%$63.46 (+19.18%)
Jul 16, 2026
11w ago
Insider Cluster
NEUTRAL ★ 3/10
$78.52 $71.97▼ −8.34%▼ −11.96%$63.46 (−19.18%)
Jul 13, 2026
11w ago
Insider Cluster
NEUTRAL ★ 2/10
$81.33 $74.63▼ −8.24%▼ −11.42%$63.46 (−21.97%)
Jul 8, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$88.57 $69.21▼ −21.86%▼ −25.13%$63.46 (−28.35%)
Jun 26, 2026
14w ago
Insider Cluster
NEUTRAL ★ 2/10
$81.57 $76.82▼ −5.82%▼ −5.54%$63.46 (−22.20%)
Jun 16, 2026
15w ago
8-K
NEUTRAL ★ 5/10
$73.27 $78.06▲ +6.54%▲ +6.34%$63.46 (−13.39%)
Jun 9, 2026
16w ago
8-K
NEUTRAL ★ 2/10
$73.35 $89.55▲ +22.09%▲ +18.46%$63.46 (−13.48%)
May 19, 2026
19w ago
Insider Cluster
NEUTRAL ★ 2/10
$71.02 $78.98▲ +11.21%▲ +10.47%$63.46 (−10.64%)
May 15, 2026
20w ago
Insider Cluster
NEUTRAL ★ 2/10
$70.15 $73.27▲ +4.45%▲ +2.87%$63.46 (−9.54%)
Showing 10 of 15

US Market Status

Market Closed — Opens Mon (64h 10m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access